Symbols

DTIL

Precision·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About DTIL

Precision Biosciences, Inc.

A clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies

Industry

Biological Technology

Established Date

Listing Date

03/28/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.precisionbiosciences.com

Security Type

Common stock

Office address

302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701

Business

Introduction

Precision BioSciences, Inc., was incorporated in Delaware in January 2006. The company is a clinical-stage gene-editing company developing in vivo gene-editing therapies using its proprietary ARCUS platform. Designed for complex editing such as gene insertion, elimination and excision, its platform leverages its unique cutting properties and smaller size to achieve clear therapeutic outcomes.

Company Financials

EPS

DTIL has released its 2025 Q4 earnings. EPS was reported at 1.05, versus the expected -0.47, beating expectations. The chart below visualizes how DTIL has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

DTIL has released its 2025 Q4 earnings report, with revenue of 34.20M, reflecting a YoY change of 5261.13%, and net profit of 20.13M, showing a YoY change of 213.46%. The Sankey diagram below clearly presents DTIL's revenue sources and cost distribution.